Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dabigatran etexilate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

NCT03311841
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 78 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 1 Interventional

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

NCT02426229
View directory record Official record
Conditions
Scleroderma, Interstitial Lung Disease
Interventions
dabigatran etexilate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational Results available

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

NCT02022020
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Aurora, Colorado • New Britain, Connecticut • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

NCT02687867
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran (Pradaxa), Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 4 Interventional Results available

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

NCT02701062
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
Device · Drug
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
San Diego, California • Stanford, California • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

NCT02104947
View directory record Official record
Conditions
Hemorrhage
Interventions
idarucizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Little Rock, Arkansas • Loma Linda, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

NCT00657150
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

NCT03539055
View directory record Official record
Conditions
Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
Interventions
Dabigatran Etexilate Oral Capsule
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational Results available

Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

NCT02149303
View directory record Official record
Conditions
Atrial Fibrillation, Hemorrhage
Interventions
Dabigatran 75 mg, Dabigatran 150 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • Brooklyn, New York • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational

Perioperative Anticoagulant Use for Surgery Evaluation Study

NCT02228798
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
3,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Evanston, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational Results available

Sequential Expansion of Comparative Effectiveness of Anticoagulants

NCT02081807
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
221,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational

Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms

NCT04192916
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
DOACs
Drug
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 30, 2026, 9:00 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

NCT07744802
View directory record Official record
Conditions
Healthy Male Participants
Interventions
Vimseltinib, Dabigatran
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

NCT04459585
View directory record Official record
Conditions
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
Interventions
Dabigatran Etexilate Mesylate, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Sep 30, 2026, 9:00 AM EDT
Completed No phase listed Observational

DOAC in Unusual Site Venous Thrombosis

NCT03778502
View directory record Official record
Conditions
Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis
Interventions
Direct Oral Anticoagulants
Drug
Lead sponsor
University of Malta
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 30, 2026, 9:00 AM EDT
Recruiting No phase listed Observational

Registry of Patients Prescribed Anticoagulation

NCT03504007
View directory record Official record
Conditions
Acute Deep Vein Thrombosis, Acute Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib DDI Study With P-gp and BCRP Substrates

NCT05368805
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Fruquintinib, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 30, 2026, 9:00 AM EDT
Terminated Phase 4 Interventional Results available

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

NCT01546883
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran etexilate (Pradaxa)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 3 Interventional

Management of Myocardial Injury After Noncardiac Surgery Trial

NCT01661101
View directory record Official record
Conditions
Myocardial Injury After Noncardiac Surgery (MINS)
Interventions
Dabigatran, Placebo (for Dabigatran), Omeprazole, Placebo (for Omeprazole)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
1,754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Kansas City, Kansas • Buffalo, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 30, 2026, 9:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

NCT02945020
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran etexilate mesylate, Odalasvir (ODV), Simeprevir (SMV)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 30, 2026, 9:00 AM EDT